ArticleCancer biomarkers : section A of Disease markers2025
CD137L and colorectal cancer prognosis: Insights from clinical and TCGA data analysis.
Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCD137L plays a substantial role in immune regulation and has been associated with tumor progression. However, its expression pattern and clinical significance in colorectal cancer remain unclear. The current study was planned to evaluate the expression levels of CD137L in colorectal cancer tissues and investigate its association with clinicopathological characteristics and patient survival.Methodology36 tissue samples were collected from colorectal cancer patients followed by RNA extracted. Following the cDNA synthesis, qRT-PCR was conducted to evaluate the CD137L expression, normalized against GAPDH and the comparative expression was determined using the ΔΔCt method. Chi-square test was applied to evaluate the relation of CD137L expression with clinical parameters. Meanwhile, the TCGA database was explored to find the relationship between the prognosis of colorectal cancer patients and different levels of CD137L expression and to analyze the distribution characteristics of differentially expressed genes.ResultsCD137L expression was significantly correlated with patient survival (P < 0.05), with higher expression observed in patients who were alive at the time of analysis. Clinical parameters such as age and gender were insignificantly associated (P > 0.05) with CD137L expression. However, a significant correlation (P = 0.03) was noted between CD137L expression and tumor staging, suggesting its potential involvement in CRC progression. Furthermore, Analysis of TCGA data showed that patients with elevated CD137L expression exhibited improved overall survival compared to those with lower expression levels. Enrichment analysis revealed that CD137 was primarily enriched with immune cell proliferation, T cell activation and Th1/Th2 balance-related signaling pathways.ConclusionCD137L may serve as a reliable indicator for forecasting the outcome of colorectal cancer patients, providing guidance for colorectal cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.